The trial NCT01968109 is evaluating the efficacy of Relatlimab as a monotherapy or in combination with Nivolumab (an anti-PD-1 antibody) in advanced solid tumors as well as NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.